PhRMA

PhRMA uneasy about "right-to-try" laws

Colorado's version of the FDA's compassionate use rule does not sit well with lobbying group Pharmaceutical Research and Manufacturers of America.

Bloomberg scrutinizes drug pricing

An analysis by Bloomberg today shows why drug pricing "keeps defying the law of gravity."

PhRMA sets up shop in the UAE

The group's offices will be in the DuBiotech research cluster.

Business briefs: Sanofi, GlaxoSmithKline, AllTrials

Sanofi named in China corruption probe; GlaxoSmithKline starts a venture capital fund; and European non-profit AllTrials outlines its transparency goals

The complexity of cracking open the data door

The complexity of cracking open the data door

By

Companies are moving toward more access to clinical trial data. Despite their new stance, the internal battles haven't quite ended, some say.

Business briefs: GSK, UCB, AZ, Biogen Idec, CVS, Roche, Forest

China's industry investigation widens beyond GlaxoSmithKline; PhRMA's European equivalent rallies patient groups to fight transparency; Biogen Idec says a patient's death is not linked to Tecfidera; parents swap walk-in clinics for office visit; Roche continues its CEO hunt; and Forest logs 6% sales growth.

Company news: PhRMA, Amgen

PhRMA talks up industry pipeline, Amgen's Aranesp fails to hit trial goals.

Congress takes a stab at IPAB

By

Congressional Republicans -- and even a few Democrats -- are pressing the attack on the Independent Payment Advisory Board for Medicare, a part of the Affordable Care Act opposed by both PhRMA and the AMA.

President's budget would deal a wallop to biopharma wallets

President's budget would deal a wallop to biopharma wallets

By

President Obama's proposed 2013 budget would mandate an estimated $156 billion in new rebates to low-income seniors through Medicare over the next decade - discounts that would come out of the pockets of drug companies and could cost tens of thousands of jobs, according to PhRMA.

To dial down DTC, let companies collaborate on ads, says ex-Merck exec

By

A former Merck exec says it's time to wind down the DTC arms race by letting companies with brands in competitive categories collaborate on disease awareness advertising.

Business Roundtable chief to replace Tauzin at PhRMA

Business Roundtable chief to replace Tauzin at PhRMA

By

PhRMA named Business Roundtable chief John Castellani as its president and CEO, tapping a longtime trade association hand to replace former Congressional kingpin Billy Tauzin.

PhRMA sweats Witty's EU samples cap

PhRMA sweats Witty's EU samples cap

By

PhRMA said the reasoning behind a sharp cap on samples mandated by its European counterpart doesn't apply in the US.

Tauzin steps down as reform goes off the rails

Tauzin steps down as reform goes off the rails

By

Billy Tauzin is stepping down as head of PhRMA amid speculation that the derailment of healthcare reform has empowered an anti-reform faction within the group. Tauzin, who has moved the group toward the Democrats and negotiated with the White House over the legislation, will leave PhRMA at the end of June.

PhRMA answers GOP leader's "appeaser" slur

By

The top Republican in the House of Representatives accused PhRMA of "appeasing" the Obama administration, which he cast as a bully who "asks for your lunch money." PhRMA responded that its pro-reform campaign is "absolutely consistent with our core principles."

PhRMA, friends air $12m pro-reform TV spot

PhRMA, friends air $12m pro-reform TV spot

By

The first execution in PhRMA's promised pro-health reform campaign -- a $12 million TV spot aimed at communicating how the legislation will impact individuals -- airs today

PhRMA pledges $80B toward drug savings

By

PhRMA has committed to finding $80 billion in savings on drugs sold in the US over 10 years, including selling drugs at half-price to seniors in the Medicare Part D "donut hole" coverage gap.

Email Newsletters

MM&M inVISION